(VIANEWS) – Celyad Oncology’s (BEL 20: CYAD.BR) shares experienced a dramatic drop of 22.77% to EUR0.36 on Thursday at 14:18 EST, marking an end to five days of consecutive losses for this stock. Meanwhile, BEL 20 index currently trades flat at EUR3,511.130 after showing signs of strength in previous sessions; suggesting this exchange session appears bullish in nature.
About CELYAD ONCOLOGY
Celyad Oncology is a clinical-stage biopharmaceutical company dedicated to the research and development of Chimeric Antigen Receptor T (CAR-T) cell therapies for cancer treatment. Their lead products, CYAD-101, CYAD-211 and CYAD-02 are currently undergoing trials in various phases for metastatic colorectal cancer, relapsed/refractory multiple myeloma as well as acute myeloid leukemia with myelodysplastic syndromes respectively. In 2004, Novartis licensed allogeneic CAR-T cells while Horizon Discovery collaborated/license agreements regarding shRNA reagents for these trials; celyad Oncology was founded and is currently headquartered out of Mont-Saint-Guibert in Belgium
Technical Analysis
CELYAD ONCOLOGY (CYAD) saw an extraordinary surge in trading volume today, with 70,628 shares trading hands – 20.7% higher than its 50-day average volume of 58,5111. This indicates that traders are taking an increasing interest in the stock and may soon cause additional price movements to occur.
Looking at CYAD’s volatility, its intraday variation average stands at negative 2.03% and over the past month its variance average was negative 1.29% while it has shown positive 6.65% variance since March 31.
Note that CYAD stock is currently considered overbought according to the stochastic oscillator – an indicator for measuring overbought and oversold conditions – suggesting it may be due for a correction soon and traders should be wary when making buying/selling decisions.
Overall, an increase in trading volume and an overbought status of CYAD could signal potential price movements over the coming days. To protect themselves and avoid potential missteps when investing, investors and traders should conduct extensive research prior to making any definitive investment decisions.
Equity Analysis
CELYAD ONCOLOGY’s twelve month trailing EPS of EUR-1.36 indicates that it is currently operating at a loss, suggesting it may not generate sufficient revenues to cover expenses and may need other sources of financing such as debt or equity in order to continue operations.
However, it’s important to keep in mind that having a negative EPS does not automatically indicate a poor investment opportunity; investors should also take into account factors such as growth potential, competitive positioning and industry trends when making this assessment. It would also be worthwhile comparing CELYAD ONCOLOGY’s EPS against its peers’ in order to get an in-depth picture of its financial performance.
More news about CELYAD ONCOLOGY (CYAD.BR).
